# CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

> **NCT05943067** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 60 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **BIOLOGICAL:** CD45RA depleted donor lymphocyte infusion (DLI)

## Key facts

- **NCT ID:** NCT05943067
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-27
- **Primary completion:** 2028-01
- **Final completion:** 2028-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943067, "CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05943067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*